University of California, San Francisco HIV/AIDS CRS

Location	UCSF Positive Health Program, Adult AIDS Clinical Trials Unit, 995 Potrero Avenue, Building 80, 4th Floor San Francisco, CA 94110 United States of America
Phone	415-476-4082 Ext. 353
CRS Coordinator	Elvira Gomez elvira.gomez@ucsf.edu 415-476-4082 University of California, San Francisco HIV/AIDS CRS 995 Potrero Avenue Bldg 80 4th Floor Room 409 San Francisco, CA 94110 United States of America
CRS Leader	Dr. Annie Luetkemeyer annie.luetkemeyer@ucsf.edu 415-476-4082 Ext. 130 University of California, San Francisco HIV/AIDS CRS Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General Hospital P.O. Box 0874 995 Potrero Avenue, 4th Floor San Francisco, CA 94110-2897 United States of America
Studies	A5128: US Genomic Sampling A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5332: REPRIEVE Trial A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function A5357: A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5372: Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (RPT-DTG PK Study) A5377: Tri-specific Antibody A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5404: SARS-CoV-2 Immune Responses after COVID-19 Therapy and Vaccine A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP) ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT) ACTG A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)